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Abstract
Hepatitis C virus (HCV) infection causes chronic liver diseases leading to hepatocellular carcinoma (HCC) and liver failure. We
have previously shown that HCV sensitizes hepatocytes to mitochondrial apoptosis via the TRAIL death receptors DR4 and
DR5. Although TRAIL and its receptors are selective targets for cancer therapy, their potential against HCC with chronic HCV
infection has not been explored yet. Here we show that HCV induces DR4/DR5-dependent activation of caspase-8 leading to
elevation of apoptotic signaling in infected cells and also present TRAIL effect in HCV-induced apoptotic signaling. HCV
induced proteolytic cleavage of caspase-9 by stimulating DR4 and DR5, resulting in subsequent cleavage of caspase-3.
Further, HCV-induced proteolytic cleavage in caspase-8, caspase-9, and caspase-3 was enhanced in the presence of
recombinant TRAIL. HCV-induced cleavage in caspase-9 and increase in caspase-3/7 activity was completely suppressed by
silencing of either DR4 or DR5. Perturbing DR4/DR5-caspase-8 signaling complex by silencing DR4 and DR5 or by chemical
inhibitor specific to caspase-8 led to decrease of HCV-induced cleavage of poly(ADP-ribose) polymerase (PARP), a substrate
for caspase-3 during apoptosis, indicating the functional role of caspase-8 in HCV-induced apoptotic signaling network.
Furthermore, TRAIL enhanced PARP cleavage in apoptotic response induced by HCV infection, indicating the effect of TRAIL
for the induction of selective apoptosis of HCC cells infected with HCV. Given the importance of apoptosis in HCC
development, our data suggest that HCV-induced DR4 and DR5 may be considered as an attractive target for TRAIL therapy
against HCC with chronic HCV infection.
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Introduction
Hepatitis C virus (HCV) infects about 170 million people
worldwide [1–4]. In the course of persistent infection, inflamma-
tion forms the pathogenetic basis of chronic hepatitis that can lead
to fibrosis, which can progress to cirrhosis and, eventually,
hepatocellular carcinoma [5]. It has been suggested that dysreg-
ulation of the apoptotic process in infected cells might be crucial
for establishing chronicity, the failure of antiviral treatment,
fibrosis progression, and neoplastic transformation [6].
Regulation of apoptosis is complex and mainly triggered by the
activation of so-called death receptors [7–9]. These receptors
include cluster of differentiation 95 (CD95)/Fas, tumor necrosis
factor (TNF)-receptor-1, and TNF-related-apoptosis-inducing-
ligand receptors (TRAIL-R) 1 and 2. In contrast to TNF-R1
and CD95/Fas, TRAIL-R1 and -R2, also known as death
receptors 4 (DR4) and 5 (DR5), induce apoptosis only in infected
or transformed tumor cells [10], but not in uninfected healthy
hepatocytes in vivo [11,12].
In addition to inducing apoptosis, these death receptors initiate
independent intracellular signaling cascades through mitochon-
drial dysfunction. Mitochondrial dysfunction plays a critical role in
integrating death receptor-initiated apoptosis into a final common
pathway by activating a caspase-dependent apoptosis [13–16].
TRAIL binding causes the formation of death-inducing signaling
complex, resulting in the activation of caspase-8. Active caspase-8
can trigger direct activation of caspase-3 and cleavage of Bid,
followed by mitochondria-dependent activation of caspase-9 via
cytochrome C release and apoptotic protease activating factor-1
(Apaf-1) activation [17]. However, the mechanism by which
PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e98171caspases are activated is still not well defined in hepatitis C virus
infection.
We recently demonstrated that co-infection with HCV and HIV
stimulates DR4 and DR5 gene expression and subsequently
activates caspase-3 signaling pathway, resulting in induction of
mitochondrial apoptosis of human hepatocytes [18]. In this study,
we demonstrate the significant contribution of caspase-8 activation
to HCV-induced DR4/DR5-dependent hepatocyte apoptosis.
Materials and Methods
Cell culture and virus
The human hepatocellular carcinoma Huh7.5.1 cells used in
this study were grown in high-glucose Dulbecco’s Modified
Eagle’s Medieum (DMEM; Hyclone) supplemented with 10%
fetal bovine serum (Hyclone; Thermo Fisher Scientific, Wilming-
ton, Delaware, USA), 100 U/ml penicillin and 0.1 mg/ml
streptomycin (Hyclone; Thermo Fisher Scientific, Wilmington,
Delaware, USA). Cell culture-derived HCV JFH-1 (HCVcc) used
in this study was propagated and prepared, as described
previously [18].
Reagents and antibodies
Recombinant human TRAIL, pan-caspase inhibitor Z-VAD-
FMK, caspase-8 specific inhibitor Z-IETD-FMK, and caspase-9
specific inhibitor Z-LEHD-FMK used in this study were
purchased from R&D systems (Abingdon). TRAIL and caspase
inhibitors were reconstituted according to the manufacturer’s
instructions. Primary antibodies used in this study include the
following: rabbit monoclonal anti-cleaved PARP (Cell signaling
Technology); mouse monoclonal anti-DR4 (Abcam); rabbit
monoclonal anti-DR5 (Cell signaling Technology); rabbit mono-
clonal anti-cleaved caspase-3 (Cell signaling Technology); rabbit
monoclonal anti-cleaved caspase-8 (Cell signaling Technology);
rabbit monoclonal anti-cleaved caspase-9 (Cell signaling Technol-
ogy); rabbit monoclonal anti-cleaved Bid (Invitrogen); mouse
monoclonal anti-HCV core (Thermo Fisher Scientific); mouse
monoclonal anti-a-tubulin (Sigma); mouse monoclonal anti-b-
actin (Sigma). The secondary antibodies used for Western blot
analysis were HRP-conjugated anti-mouse IgG (Santa Cruz
Biotechnology) and HRP-conjugated anti-rabbit IgG (Santa Cruz
Biotechnology).
Small interfering RNA transfection
siGENOME non-targeting siRNA pool #1 and ON-TAR-
GETplus SMARTpool small interfering RNA (siRNA) for DR4
(NM_003844) and DR5 (NM_003842) were purchased from
Dharmacon. Huh7.5.1 cells were transfected with siRNAs (50 nM)
using Lipofectamine RNAiMAX transfection reagent according to
the manufacturer’s instructions (Invitrogen) prior to HCVcc
infection.
Real-time qRT-PCR
To analyze the expression levels of DR4 and DR5, total cellular
RNA was extracted from Huh7.5.1 cells using RNeasy Mini kit
(Qiagen) and subsequently, complementary DNA was synthesized
by using GeneAmp RNA PCR kit (Applied Biosystems) according
to the manufacturer’s instructions. Power SYBR Green PCR
Master Mix (Applied Biosystems) was used to quantify the cellular
RNA levels. The following primer sets were used for RT-PCR:
DR4 forward, 59-CTGAGCAACGCAGACTCGCTGTCCAC;
DR4 reverse, 59-TCAAAGGACACGGCAGAGCCTGTGCCA;
DR5 forward, 59-GGGAGCCGCTCATGAGGAAGTTGG;
DR5 reverse, 59-GGCAAGTCTCTCTCCCAGCGTCTC;
GNB2L1 forward, 59-GACCATCATCATGTGGAAACTGA;
GNB2L1 reverse, 59-CCGTTGTGAGATCCCAGAGG. GNB2L1
was used as an internal control. Real-time qPCR was conducted by
using a StepOnePlus Real-Time PCR System (Applied Biosystems).
Western blot analysis
Cells were resuspended in lysis buffer (50 mM Tris-HCl, 1 mM
EDTA, 50 mM NaF, 1 mM Na3VO4, 1% Triton X-100,
150 mM NaCl, and 10 mg/ml aprotinin) supplemented with
protease inhibitor cocktail (Roche). Whole cell lysates were
subjected to SDS-PAGE, transferred to nitrocellulose membrane
(Millipore), and Western blot analyzed with antibodies against the
indicated proteins.
Caspase-3/7 activity assay
Caspase-3/7 activity in HCV-infected cells was measured using
the Caspase-Glo 3/7 assay kit according to the manufacturer’s
instruction (Promega). Briefly, Huh7.5.1 cells transfected with
non-targeting (NT) or specific-targeting siRNA pools for DR4 and
DR5 were infected with HCVcc. At 3 days post-infection, caspase-
Figure 1. HCV infection stimulates DR4 and DR5 expression.
(A-C) Quantitative analyses of DR4 and DR5 gene expression in HCV-
infected cells. Huh7.5.1 cells were infected with HCVcc. At 3 days post-
infection, cells were used for analysis of DR4 and DR5 gene expression.
(A and B) Intracellular mRNA level of DR4 and DR5 genes were analyzed
by real-time qRT-PCR. Human GNB2L1 was used to normalize changes
in DR4 and DR5 gene expression (mean6SD; n=3; *p,0.001). (C) The
protein expression levels of DR4 and DR5 were analyzed by Western
blotting with anti-DR4 and DR5 antibodies. The expression of HCV core
protein was analyzed by Western blotting with anti-HCV core antibody.
b-actin was used as an internal loading control. The relative intensity of
DR4 and DR5 expression normalized to b-actin was analyzed by ImageJ.
doi:10.1371/journal.pone.0098171.g001
Caspase-8 Is Required for Hepatocyte Apoptosis in HCV
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Multi-Mode Microplate Reader (BioTek).
Statistical analysis
Statistical analysis was performed using a paired student’s t-test.
Results were expressed as means 6 standard deviation of at least
three sample replicates.
Results
HCV infection stimulates DR4 and DR5 gene expression
We have recently shown that HCV infection activates DR4 and
DR5-mediated intrinsic apoptotic signaling in human hepatocytes
[18], consistent with other reports [19–21]. To evaluate critical
determinants on DR4/DR5-dependent apoptotic signaling net-
work induced by HCV infection, we first examined DR4 and DR5
gene expression. As shown in Figs. 1A and B, HCV infection
stimulated the level of both DR4 and DR5 mRNA expression,
consistent with previous reports [18,19], and induced consistent
increase in DR4 and DR5 protein expression as evidenced by
Western blotting with antibodies specific to DR4 and DR5
(Fig. 1C). These results indicate that HCV infection stimulates
DR4 and DR5 gene expression to promote DR4/DR5-dependent
apoptotic signaling.
HCV infection activates caspase-8-dependent apoptosis
signaling by stimulating DR4 and DR5
TRAIL induces the recruitment of Fas-associated death domain
and procaspase-8 to DR4 and DR5, leading to activation of
caspase-8 and subsequent caspase-9/-3-dependent apoptotic
signaling pathway [22–25]. To investigate caspase-8-mediated
apoptotic signaling by stimulating DR4 and DR5 induced by
HCV infection, we analyzed whether HCV induces caspase-8
activation leading to subsequent cleavage in caspase-9 and
caspase-3 in Huh7.5.1 cells. As shown in Fig. 2A, HCV infection
increased the level of cleaved caspase-9 and caspase-3. Further-
more, treatment of HCV-infected Huh7.5.1 cells with recombi-
nant TRAIL elevated the level of cleaved caspase-8, caspase-9 and
caspase-3, indicating that TRAIL enhances caspase-8 dependent
apoptotic signaling via DR4 and DR5 receptors (Fig. 2A).
Figure 2. HCV infection activates DR4/DR5-dependent caspase cascade. (A) Western blot analysis of Bax and cleaved caspase-8, caspase-9,
and caspase-3 in HCV-infected cells. Huh7.5.1 cells infected with HCVcc in the absence or presence of recombinant TRAIL (100 ng/ml) were used for
Western blot analysis with antibodies against the indicated proteins. b-actin was used as an internal loading control. Samples: MC, media control. (B
and D) Silencing DR4 and DR5 prevent caspase-9 cleavage and caspase-3/7 activity induced by HCV infection. Huh7.5.1 cells transfected with non-
targeting (NT) or gene-specific (ST) siRNA pools targeting DR4 and DR5, respectively, were infected with HCVcc. At 3 days post-infection, the mRNA
levels of DR4 and DR5 were analyzed by real-time qRT-PCR (B) (mean6SD; n=3; *p,0.05, **p,0.01) and whole cell lysates were analyzed by Western
blotting with antibodies specific to the indicated proteins (C). (D) The activity of caspase-3/7 was measured according to manufacturer’s instructions
(mean6SD; n=3; *p,0.005).
doi:10.1371/journal.pone.0098171.g002
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activation, a key mediator of apoptosis, in Huh7.5.1 cells (Fig. 2A)
[26]. HCV infection also increased caspase-3/7 activity in
Huh7.5.1 cells (Fig. 2C). Further, we examined the significance
of DR4 and DR5 on apoptotic signaling pathway activated by
HCV infection. As shown in Figs. 2C and D, HCV-induced
caspase-9 cleavage and increase in caspase-3/7 activity was
inhibited by silencing either DR4 or DR5 as evidenced by qRT-
PCR (Fig. 2B). Together, these results indicate that caspase-8
activation via DR4 and DR5 is required to promote HCV-
induced apoptotic signaling.
HCV infection elevates DR4/DR5-mediated PARP
cleavage via caspase-8 activation
PARP cleavage by caspase activation is a hallmark of apoptosis
[27,28]. Thus, we investigated proteolytic cleavage of PARP via
DR4/DR5-mediated caspase activation in HCV-infected
Huh7.5.1 cells. As shown in Fig. 3A, a notable increase in cleaved
PARP level was detected in HCV-infected cells compared to
uninfected cells (see lane 3). This increase was further augmented
by treatment with recombinant TRAIL (Fig. 3A, lane 6),
suggesting that TRAIL may induce enhanced apoptosis via DR4
and DR5 receptors of HCV-infected cells. Interference of caspase-
8-mediated apoptotic signaling network by silencing either DR4 or
DR5 prevented HCV-induced PARP cleavage (Fig. 3B). Next, we
examined whether HCV-induced PARP cleavage is mediated by
caspase-8 activation using caspase inhibitors specific to caspase-1/
3, caspase-8, and caspase-9, respectively. As shown in Fig. 3C,
HCV-induced increase in cleaved PARP was suppressed by
inhibiting caspase activity. Here, we note that caspase-8 activation,
an upstream effector of caspase-9 and caspase-3, mediates DR4/
DR5-mediated PARP cleavage in HCV-infected cells. We also
analyzed that HCV-induced PARP cleavage is dose-dependently
promoted by TRAIL treatment (Fig. 3D). By inhibiting caspase-8
activity, the functional significance of caspase-8 for DR4/DR5-
dependent apoptotic signaling in HCV-infected cells was revealed
through suppression of HCV-induced Bid cleavage and subse-
quent caspase-9 cleavage (Fig 4). Caspase-8 activation promotes
cleavage of Bid and subsequent translocation of truncated Bid to
Figure 3. HCV-induced DR4/DR5-mediated caspase-8 activity affects PARP cleavage. (A) Western blot analysis of cleaved PARP in HCV-
infected cells. Whole cell lysates extracted from HCV-infected Huh7.5.1 cells grown in the absence or presence of recombinant TRAIL (100 ng/ml)
were analyzed by Western blotting with antibodies specific to the indicated proteins. (B) Huh7.5.1 cells transfected with non-targeting (NT) or gene-
specific (ST) siRNA pools targeting DR4 and DR5, respectively, were infected with HCVcc. At 3 days post-infection, whole cell lysates were analyzed by
Western blotting with antibodies specific to the indicated proteins. (C) HCV-infected Huh7.5.1 cells stimulated with recombinant TRAIL (100 ng/ml)
were treated with Z-VAD-FMK (pan inhibitor; 40 mM), Z-IETD-FMK (caspase-8 inhibitor; 40 mM), and Z-LEHD-FMK (caspase-9 inhibitor; 40 mM),
respectively, for 72 h before harvest. The expression level of PARP was analyzed by Western blotting with anti-cleaved PARP antibody. (D) Western
blot analysis showing dose-dependent effects of recombinant TRAIL on PARP cleavage in HCV-infected cells. HCV-infected Huh7.5.1 cells were
treated with recombinant TRAIL for 72 h at the indicated dose points. Whole cell lysates were analyzed by Western blotting with anti-cleaved PARP
antibody. Samples: MC, media control. (A-D) b-actin was used as an internal loading control.
doi:10.1371/journal.pone.0098171.g003
Figure 4. HCV-induced caspase-8 activity modulates caspase-9
cleavage. Huh7.5.1 cells were infected with HCVcc in the absence or
presence of caspase-8 inhibitor (20 mM) for 72 h before harvest. The
expression levels of truncated Bid (t-Bid) and cleaved caspase-9 were
analyzed by Western blotting with antibodies specific to t-Bid and
cleaved caspase-9. a-tubulin was used as an internal loading control.
The relative intensity of t-Bid and cleaved caspase-9 normalized to a-
tubulin was analyzed by ImageJ. Samples: MC, media control.
doi:10.1371/journal.pone.0098171.g004
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cytochrome C release [17,29]. Together, these results demonstrate
that HCV infection promotes DR4/DR5-mediated PARP cleav-
age via translocation of caspase 8-truncated Bid.
Discussion
Apoptosis, or programmed cell death, is a process in which cells
activate intracellular death pathways to terminate themselves
systematically in response to a wide variety of stimuli [30,31].
Previous studies have shown that the severity of liver damage in
chronic HCV is associated with the degree of hepatocyte apoptosis
[32,33]. However, the contribution of apoptosis or the molecular
mechanisms that cause liver cell damage during HCV infection
have not yet been clearly defined. Recently, death receptor DR4/
DR5 has been recognized as a specific mediator of HCV-induced
hepatocyte apoptosis [34–36]. Thus, we sought to evaluate critical
determinants, particularly caspase-8 activation, of the DR4/DR5-
dependent apoptotic signaling pathway induced by HCV infec-
tion.
A therapeutic potential of TRAIL for liver cancer with
persistent HCV infection has been overlooked. TRAIL receptors
including DR4 and DR5 are very attractive targets for cancer
therapy [37]. Hence, in this work, our research purpose was (1) to
examine the role of caspase-8, one of important determinants of
DR4/DR5-mediated apoptosis signaling network during HCV
infection as well as (2) to illuminate the possibility of TRAIL use
for therapy of hepatocellular carcinoma caused by HCV infection.
It is commonly assumed that virus clearance requires the
destruction of infected cells by virus-specific cytotoxic T-lympho-
cytes via the CD95 receptor, TNF-receptor-1 and TRAIL
receptors DR4 and DR5. If death receptor-mediated apoptosis
works adequately, it is beneficial for the organism and may lead to
elimination of virus-infected cells. However, dysregulation of this
system might result in liver damage. Therefore, TRAIL receptors,
which selectively kill virus-infected cells while leaving uninfected
cells intact, have evolved as a prime physiological mechanism in
order to selectively eliminate virus-infected cells [38–40]. We and
others have previously shown the stimulation of DR4 and DR5 in
the liver of patients with chronic HCV as well as in HCV-infected
cells [11,18,21,39,41]. In contrast, few reports have suggested that
HCV infection does not affect DR4 or DR5 expression [20,42]. In
this study, we clarify that HCV infection stimulates DR4 and DR5
gene expression at both the transcriptional and translational levels
in Huh7.5.1 cells, as evidenced by qRT-PCR and Western blot
analysis (Fig. 1). Consistent with our results, Zhu et al have shown
that HCV infection upregulates DR4 and DR5 expression levels
and triggers TRAIL-mediated apoptosis in human hepatocellular
carcinoma LH86 cells [21]. They also demonstrated that TRAIL
expression is correlated with the number of apoptotic LH86 cells
[21].
A number of liver diseases are characterized by elevated caspase
activation and apoptosis. Caspase is a cysteine protease which
plays a critical role in initiating and executing the apoptotic
signaling by degrading several cellular components, resulting in
the apoptotic phenotype [43]. In death receptor-mediated
apoptosis, CD95L-, TNF- and TRAIL-induced signal transduc-
tion leads to the formation of a death-inducing signaling complex
which results in the proteolytic processing of caspase-8 and
activation of downstream effector caspases such as caspase-3,
caspase-6, and caspase-7, known as an extrinsic pathway
[38,44,45]. The intrinsic apoptotic pathway regulated by the B
cell lymphoma 2 (Bcl-2) family proteins results in activation of
caspase-9, which in turn activates the downstream effector
caspases [43]. Effector caspases are a class of enzymes responsible
for the execution of apoptosis and their activation was observed in
a considerable percentage of hepatocytes in liver biopsies from
chronic HCV infection [46]. Lan et al have shown that HCV
infection induces TRAIL-mediated mitochondrial apoptosis via
caspase-9 activation [20], however, the precise mechanism still
remains to be clarified. In Fig. 2, we show that HCV infection
induces the activation of caspase-8 and subsequent downstream
effectors caspase-9 and caspase-3 in response to TRAIL. The
functional significance of DR4 and DR5 in activation of caspase-
dependent apoptotic signaling induced by HCV infection was also
clarified by reduction of caspase-3/7 activity by DR4 and DR5
silencing (Figs. 2C and D). We propose that HCV infection
promotes caspase-8 activity followed by activation of caspase-9
and caspase-3, as evidenced by suppression of DR4/DR5-
mediated PARP cleavage via translocation of caspase 8-truncated
Bid. Taken together, our data demonstrate the functional
significance of DR4/DR5-mediated caspase-8 activation as a
critical mediator of HCV-induced apoptosis. Efforts to inhibit the
TRAIL apoptotic program may be warranted to retard the
progression of HCV-related advanced liver disease.
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